EXOTLR1/2-STING: A Dual-Mechanism Stimulator of Interferon Genes Activator for Cancer Immunotherapy
Source abstract
Abstract
As natural agonists of the stimulator of interferon genes (STING) protein, cyclic dinucleotides (CDNs) can activate the STING pathway, leading to the expression of type I interferons and various cytokines. Efficient activation of the STING pathway in antigen-presenting cells (APCs) and tumor cells is crucial for antitumor immune response. Tumor-derived exosomes can be effectively internalized by APCs and tumor cells and have excellent potential to deliver CDNs to the cytoplasm of APCs and tumor cells. Here, we leverage tumor exosomes as a delivery platform, designing an EXO TLR1/2-STING loaded with CDNs. To achieve efficient loading of CDNs onto exosomes, we chemically conjugated CDNs with Pam 3 CSK 4, a compound featuring multiple fatty acid chains, resulting in Pam 3 CSK 4 –CDG SF . Utilizing the high lipophilicity of Pam 3 CSK 4, Pam 3 CSK 4 –CDG SF could be efficiently loaded onto the exosomes through simple incubation. Moreover, as an agonist for Toll-like receptor 1/2, Pam 3 CSK 4 also exhibits robust immunological synergistic effects in conjunction with CDNs. EXO TLR1/2-STING effectively induced the activation of APCs and triggered tumor cell death, producing a favorable antitumor therapeutic effect. It also demonstrated significant synergistic effects with immune checkpoint therapies.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: interferon and immune responses · Viral Infections and Vectors · Inflammasome and immune disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Lab of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry
Tsinghua University
Beijing Institute for Brain Disorders
Center for Synthetic and Systems Biology
Funding
National Key Research and Development Program of China · National Natural Science Foundation of China
References (59)
Show source-provided references
1. 10.1038/nature0731710.1038/nature07317 ↗
2. 10.1038/nature1042910.1038/nature10429 ↗
3. 10.1038/nri392110.1038/nri3921 ↗
4. 10.1002/adbi.20160001310.1002/adbi.201600013 ↗
5. 10.1038/s41565-018-0342-510.1038/s41565-018-0342-5 ↗
6. 10.1126/science.aau081010.1126/science.aau0810 ↗
7. 10.1038/s41565-021-00962-910.1038/s41565-021-00962-9 ↗
8. 10.1038/s41563-022-01251-z10.1038/s41563-022-01251-z ↗
9. 10.1038/s41565-023-01447-710.1038/s41565-023-01447-7 ↗
10. 10.1126/sciimmunol.abn661210.1126/sciimmunol.abn6612 ↗
11. 10.1016/j.jconrel.2022.03.05410.1016/j.jconrel.2022.03.054 ↗
12. 10.1021/acscentsci.3c0131010.1021/acscentsci.3c01310 ↗
13. 10.1158/0008-5472.CAN-15-188510.1158/0008-5472.CAN-15-1885 ↗
14. 10.1038/s43018-020-0028-410.1038/s43018-020-0028-4 ↗
15. 10.1073/pnas.191969011710.1073/pnas.1919690117 ↗
16. 10.1016/j.ccell.2020.11.00610.1016/j.ccell.2020.11.006 ↗
17. 10.1038/s41586-023-05880-510.1038/s41586-023-05880-5 ↗
18. 10.1126/sciadv.add856410.1126/sciadv.add8564 ↗
19. 10.1016/j.canlet.2017.05.02610.1016/j.canlet.2017.05.026 ↗
20. 10.1038/s43018-022-00468-w10.1038/s43018-022-00468-w ↗
21. 10.1038/s41565-024-01624-210.1038/s41565-024-01624-2 ↗
22. 10.1002/anie.20240703710.1002/anie.202407037 ↗
23. 10.1016/j.celrep.2018.11.04710.1016/j.celrep.2018.11.047 ↗
24. 10.1158/2326-6066.CIR-13-012310.1158/2326-6066.CIR-13-0123 ↗
25. 10.1016/j.celrep.2015.04.03110.1016/j.celrep.2015.04.031 ↗
26. 10.1016/j.molmed.2019.02.00710.1016/j.molmed.2019.02.007 ↗
27. 10.1073/pnas.221427811910.1073/pnas.2214278119 ↗
28. 10.1038/nrm.2017.12510.1038/nrm.2017.125 ↗
29. 10.1186/s12943-023-01898-510.1186/s12943-023-01898-5 ↗
30. 10.7150/thno.5257010.7150/thno.52570 ↗
31. 10.1038/s41467-019-11718-410.1038/s41467-019-11718-4 ↗
32. 10.1038/8543810.1038/85438 ↗
33. 10.1038/s41590-021-00899-010.1038/s41590-021-00899-0 ↗
34. 10.1038/s41577-022-00763-810.1038/s41577-022-00763-8 ↗
35. 10.1021/ja211725s10.1021/ja211725s ↗
36. 10.1002/anie.20130887510.1002/anie.201308875 ↗
37. 10.1021/acs.chemrev.9b0083310.1021/acs.chemrev.9b00833 ↗
38. 10.1021/acs.accounts.2c0036010.1021/acs.accounts.2c00360 ↗
39. 10.1021/acs.bioconjchem.0c0052210.1021/acs.bioconjchem.0c00522 ↗
40. 10.3390/pharmaceutics1501006610.3390/pharmaceutics15010066 ↗
41. 10.3390/pharmaceutics1501002110.3390/pharmaceutics15010021 ↗
42. 10.1038/s41565-021-00931-210.1038/s41565-021-00931-2 ↗
43. 10.1039/D0CC06959K10.1039/D0CC06959K ↗
44. 10.31635/ccschem.022.20220185910.31635/ccschem.022.202201859 ↗
45. 10.1007/s12274-022-4282-x10.1007/s12274-022-4282-x ↗
46. 10.6023/cjoc20221104910.6023/cjoc202211049 ↗
47. 10.1039/C4CC07511K10.1039/C4CC07511K ↗
48. 10.1039/C8CC04860F10.1039/C8CC04860F ↗
49. 10.1002/anie.20120491010.1002/anie.201204910 ↗
50. 10.1038/s41586-018-0287-810.1038/s41586-018-0287-8 ↗
51. 10.31635/ccschem.023.20230275110.31635/ccschem.023.202302751 ↗
52. 10.1038/s41565-023-01401-710.1038/s41565-023-01401-7 ↗
53. 10.1007/s10495-019-01532-010.1007/s10495-019-01532-0 ↗
54. 10.1038/nrclinonc.2017.10110.1038/nrclinonc.2017.101 ↗
55. 10.1038/s41591-018-0014-x10.1038/s41591-018-0014-x ↗
56. 10.1038/ni.270310.1038/ni.2703 ↗
57. 10.1136/jitc-2020-00118210.1136/jitc-2020-001182 ↗
58. 10.1039/D2CS00486K10.1039/D2CS00486K ↗
59. 10.1002/chem.20110021710.1002/chem.201100217 ↗